Novartis Ag (NVS) Receivables - Other (2017 - 2025)

Novartis Ag's Receivables - Other history runs 9 years deep, the most recent figure standing at $1.1 billion for Q4 2025.

• In Q4 2025, Receivables - Other rose 4.01% year-over-year to $1.1 billion; the TTM figure through Dec 2025 stood at $1.1 billion (up 4.01% YoY), while the FY2025 annual figure was $1.1 billion, up 4.01% from the prior year.
• Receivables - Other came in at $1.1 billion for Q4 2025 at Novartis Ag, up from $1.1 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.3 billion in Q4 2023 to a low of $793.0 million in Q4 2021.
• A 5-year average of $1.0 billion and a median of $1.1 billion in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other dropped 17.65% in 2021 and jumped 30.69% in 2023, its largest moves.
• Novartis Ag's Receivables - Other stood at $793.0 million in 2021, then rose by 20.81% to $958.0 million in 2022, then surged by 30.69% to $1.3 billion in 2023, then declined by 12.38% to $1.1 billion in 2024, then advanced by 4.01% to $1.1 billion in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.1 billion, $1.1 billion, and $1.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison